Erudio Healtherudio.com
Drug
Letrozole trials: what clinicians said in public
No HCP commentary report on a trial studying letrozole yet. Erudio has found public clinician commentary on 27 clinical trials studying letrozole, including PATINA, RIGHT Choice, RxPONDER and TAILORx. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PATINA NCT02947685 · Alliance Foundation Trials, LLC. DeepView → | hormone receptor-positive, HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| TAILORx NCT00310180 · National Cancer Institute (NCI) DeepView → | hormone receptor-positive HER2-negative node-negative breast cancer | Phase 3 | Deep | View | |||
| RxPONDER NCT01272037 · National Cancer Institute (NCI) DeepView → | Not given | Phase 3 | Deep | View | |||
| RIGHT Choice NCT03839823 · Novartis Pharmaceuticals DeepView → | premenopausal or perimenopausal HR-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| persevERA NCT04546009 · Hoffmann-La Roche DeepView → | Not given | Phase 3 | Deep | View | |||
| MONALEESA-7 NCT02278120 · Novartis Pharmaceuticals DeepView → | premenopausal HR-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| PHERGain NCT03161353 · MedSIR DeepView → | HER2-positive early breast cancer | Phase 2 | Deep | View | |||
| MINDACT NCT00433589 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | breast cancer with 0 to 3 positive nodes | Phase 3 | Deep | View | |||
| CAMBRIA-2 NCT05952557 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| EMBER-4 NCT05514054 · Eli Lilly and Company DeepView → | ER+, HER2- early breast cancer | Phase 3 | Deep | View | |||
| CAMBRIA-1 NCT05774951 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| SERENA-6 NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| BYLieve NCT03056755 · Novartis Pharmaceuticals DeepView → | PIK3CA-mutated HR+ HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| ROSALINE NCT04551495 · Jules Bordet Institute DeepView → | ER+ HER2-negative invasive lobular breast carcinoma | Phase 2 | Deep | View | |||
| FourLight-3 NCT06760637 · Pfizer DeepView → | HR-positive HER2-negative advanced/metastatic breast cancer | Phase 3 | Deep | View | |||
| RAMP 301 NCT06072781 · Verastem, Inc. DeepView → | recurrent low-grade serous ovarian cancer | Phase 3 | Deep | View | |||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| TRAK-ER NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||
| NRG-GY019 NCT04095364 · NRG Oncology StandardView → | stage II-IV low-grade serous ovarian cancer | Phase 3 | Standard | View | |||
| INAVO123 NCT06790693 · Hoffmann-La Roche StandardView → | endocrine-sensitive PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| AMBRE NCT04158362 · UNICANCER StandardView → | high burden ER+/HER2- breast cancer with visceral metastasis | Phase 3 | Standard | View | |||
| EvoPAR-Breast01 NCT06380751 · AstraZeneca StandardView → | first-line BRCA1/BRCA2/PALB2-mutated HR-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| VERITAC-3 NCT05909397 · Pfizer FocusedView → | Not given | Phase 3 | Focused | View | |||
| MORPHEUS-panBC NCT03424005 · Hoffmann-La Roche FocusedView → | metastatic breast cancer | Phase 1/Phase 2 | Focused | View | |||
| MONARCH 3 NCT02246621 · Eli Lilly and Company FocusedView → | first-line HR+/HER2- advanced breast cancer | Phase 3 | Focused | View | |||
| PELOPS NCT02764541 · Dana-Farber Cancer Institute FocusedView → | early invasive lobular or ductal breast cancer | Phase 2 | Focused | View | |||
| AMALEE NCT03822468 · Novartis Pharmaceuticals FocusedView → | first-line HR-positive HER2-negative advanced breast cancer | Phase 2 | Focused | View | |||